Related Experiment Video

Updated: Apr 21, 2026

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice
09:26

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice

Published on: March 23, 2016

20.9K

[The option of neuroprotective therapeutics for glaucoma]

Shuyu Xiong1, Xun Xu1

  • 1Department of Ophthalmology, Shanghai Jiaotong University Affiliated First People's Hospital, Shanghai 200080, China.

[Zhonghua Yan Ke Za Zhi] Chinese Journal of Ophthalmology
|November 12, 2014
PubMed

Insights

Small peptides offer a promising, next-generation approach to neuroprotection for glaucoma, a leading cause of irreversible blindness. These small-molecule bioactive peptides demonstrate high efficacy and safety for managing retinal ganglion cell (RGC) degeneration.

Area of Science:

  • Ophthalmology
  • Neuroscience
  • Pharmacology

Background:

  • Glaucoma is a leading cause of irreversible blindness globally.
  • It involves progressive neurodegeneration of retinal ganglion cells (RGCs).
  • Key mechanisms include neurotrophic factor deprivation and glutamate excitotoxicity via NMDAR.

Purpose of the Study:

  • To review current developments in neuroprotective drugs for glaucoma.
  • To evaluate small-molecule therapeutics, recombinant proteins, and small-molecule bioactive peptides.
  • To identify the most promising therapeutic strategy for future glaucoma management.

Main Methods:

  • Literature review of current research on glaucoma neuroprotective agents.
  • Comparative analysis of small-molecule therapeutics, recombinant proteins, and small-molecule bioactive peptides.
  • Assessment of drug characteristics including target specificity, potency, toxicity, immunogenicity, and cost-effectiveness.

Main Results:

  • Small-molecule bioactive peptides exhibit high target specificity, potency, and low toxicity.
  • Compared to recombinant therapeutics, peptides offer lower immunogenicity and higher cost-effectiveness.
  • These advantages position small peptides as a potentially superior option for glaucoma neuroprotection.

Conclusions:

  • Small-molecule bioactive peptides represent a highly promising therapeutic avenue for glaucoma.
  • Their favorable characteristics make them a strong candidate for next-generation glaucoma treatments.
  • Further development of peptide-based therapies could significantly impact glaucoma management and vision preservation.

More Related Videos

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

13.8K
Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

2.1K

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.7K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.7K
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
256